Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering (IPO) application of 4,705,150 shares accepted for review by the Beijing Stock Exchange. This marks the first such move by a pre-revenue biotech company following the China Securities Regulatory Commission’s (CSRC) tightening of IPO rules on August 27, 2023. The potential IPO could raise RMB 349 million (USD 49.15 million), which is designated for novel biologic drug research and development (R&D), clinical program investment, and supplementary working capital.
Mabworks Bio’s Financials and Focus on Innovative Antibody Drugs
Mabworks Bio, which concentrates on the R&D and industrialization of innovative antibody targeted drugs, reported revenues of only RMB 1.46 million for the first half of 2024, alongside a net loss of RMB 126 million. The company’s lead program, MIL62, an in-house developed third-generation CD20-targeted monoclonal antibody (mAb), has received a breakthrough therapy designation (BTD) from the National Medical Products Administration (NMPA) for the treatment of primary membranous nephropathy (PMN). Other programs under development include MBS303/MSC303 and MBS314.
Partnerships and Industry Collaborations
Mabworks Bio is partnered with several high-profile Chinese companies, including Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), Livzon Pharmaceutical Group Inc. (HKG: 1513), and Betta Pharmaceuticals Co., Ltd (SHE: 300558), among others, indicating its strategic industry collaborations.- Flcube.com